IP Library › Granted Patent US 12,240,886
Granted Patent B2
US 12,240,886 · App. 17/814,401 · Granted Mar 4, 2025

Peptide-HLA complexes and methods of producing same

Inventors: Naoto Hirano (Toronto, CA); Munehide Nakatsugawa (Sapporo, JP); Muhammed Aashiq Rahman (Brisbane, AU); Kenji Murata (Toronto, CA)
Assignee: University Health Network
C07K14/70539A61K39/4611A61K39/4632A61K39/464488A61K39/464491C07K7/06C12N5/0638C12N5/0639C07K2319/02C07K2319/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,240,886
App. No.
17/814,401
Granted
Mar 4, 2025
Kind
B2
Abstract

There is provided herein, the use of mammalian derived HLA class I molecule for in vitro peptide exchange. For example, there is provided a method of producing an HLA class I molecule complexed to a pre-selected peptide comprising: (a) providing a mammalian derived HLA class I molecule complexed to an existing peptide; (b) incubating, in vitro, the HLA class I molecule complexed to the existing peptide with the pre-selected peptide, wherein the pre-selected peptide is at a concentration sufficient to replace the existing peptide to produce the HLA class I molecule complexed to the pre-selected peptide; and the HLA class I molecule comprises α1, α2, α3 and β2m domains.

Claims (20)

1. A polypeptide comprising an α1, α2 and α3 domain of an HLA class I molecule, a signal peptide at the N terminus and a 6×His tag joined by a GS linker at the C terminus, wherein:

(a) the HLA class I molecule is HLA-A and comprises the α1, α2 and α3 domain of any of SEQ ID NOs. 2, 4, 6, 8, 10, and 12;

(b) the HLA class I molecule is HLA-B and comprises the α1, α2 and α3 domain of any of SEQ ID NOs. 14, 16, 18, 20, and 22;

(c) the HLA class I molecule is HLA-C and comprises the α1, α2 and α3 domain of any of SEQ ID NOs. 24, 26, 28, and 30; or

(d) the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, or 30.

2. A compound comprising the polypeptide of claim 1 complexed with a β2m domain.

3. A multimer of at least two compounds according to claim 2 .

4. The multimer of claim 3 , wherein an antibody recognizing the 6×His tag dimerizes the at least two compounds.

5. The polypeptide of claim 1 , which is soluble.

6. The compound of claim 2 , wherein the β2m domain is exogenous.

7. The polypeptide of claim 1 , wherein the HLA class I molecule is HLA-A and comprises the α1, α2 and α3 domains of any of SEQ ID NOs. 2, 4, 6, 8, 10, or 12.

8. The polypeptide of claim 1 , wherein the HLA class I molecule is HLA-B and comprises the α1, α2 and α3 domains of any of SEQ ID NOs. 14, 16, 18, 20, or 22.

9. The polypeptide of claim 1 , wherein the HLA class I molecule is HLA-C and comprises the α1, α2 and α3 domains of any of SEQ ID NOs. 24, 26, 28, or 30.

10. The polypeptide of claim 1 , wherein the α3 domain of the HLA class I molecule is the mouse K b α3 domain.

11. The polypeptide of claim 1 , wherein in the α2 domain of the HLA class I molecule, Gln has been replaced with Glu at position 115.

12. The compound of claim 2 , wherein the HLA class I molecule comprises the amino acid sequence set forth in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, or 30.

13. The multimer of claim 3 , wherein the multimer is a dimer, trimer, tetramer, or pentamer.

14. The compound of claim 2 , wherein the HLA class I molecule is complexed to a pre-selected peptide.

15. The compound of claim 14 , wherein the pre-selected peptide comprises a portion of a polypeptide selected from the group consisting of a WT1 polypeptide, a MIA polypeptide, an ALX1 polypeptide, a GAPDHS polypeptide, an S100B polypeptide, an ABC5 polypeptide, an EXTL1 polypeptide, a CPN1 polypeptide, a TSPAN10 polypeptide, a GJB1 polypeptide, an MITF polypeptide, a DUSP4 polypeptide, a cyclin-A1 polypeptide, an HERV-K-MEL polypeptide, an LAGE-1 polypeptide, a MAGE polypeptide, an LAGE-2 polypeptide, an SSX-2 polypeptide, an XAGE-1b polypeptide, a CEA polypeptide, a gp100 polypeptide, an NY-BR-1 polypeptide, a TRP-2 polypeptide, a tyrosinase polypeptide, a CD274 polypeptide, a CPSF polypeptide, a cyclin D1 polypeptide, an IDO1 polypeptide, an mdm-2 polypeptide, a p53 polypeptide, a PRAME polypeptide, a SOX10 polypeptide, a survivin polypeptide, a telomerase polypeptide, a wild-type MART1 polypeptide, a heteroclitic MART1 polypeptide, a wild-type NY-ESO-1 polypeptide, a heteroclitic NY-ESO-1 polypeptide, an HIV pol polypeptide, and an HTLV-1 tax polypeptide.

16. The compound of claim 14 , wherein the pre-selected peptide comprises an amino acid sequence selected from the amino acid sequences set forth in SEQ ID NOs: 35-122.

Continuity (3)
Division 16095913
Provisional Application 62328325 · Apr 27, 2016
Related Publication 20230192809A1 · Jun 22, 2023
References Cited (44)
US 20030124613A1 · Hildebrand et al. · 2003 [cited by applicant]
US 20100168390A1 · Brix et al. · 2010 [cited by applicant]
CN 101687910A · 2010 [cited by applicant]
WO WO2017185169A1 · 2017 [cited by applicant]
Allard, M., et al., “Soluble HLA-I/Peptide Monomers Mediate Antigen-Specific CD8 T Cell Activation through Passive Peptide Exchange with Cell-Bound HLA-I Molecules,” The Journal of Immunology 192(11):5090-5097, The Amer… [cited by applicant]
Altman, J., et al., “Phenotypic analysis of antigen-specific T lymphocytes,” Science 274(5284):94-96, American Association for the Advancement of Science, United States (Oct. 1996). [cited by applicant]
Bakker, A., et al., “Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7,” Proc Natl Acad Sci, 105(10):3825-3830, National Academy of Sciences, Unit… [cited by applicant]
Butler, M., et al., “A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles,” Int Immunol 22(11):863-873, Oxford University Pr… [cited by applicant]
Butler, M., et al., “Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell,” Clin Cancer Res 13(6):1857-1867, American Association for Cancer Research Inc., Uni… [cited by applicant]
Chen, X., et al., “Fusion protein linkers: Property, design and functionality” Adv Drug Deliv Rev 65(10):1357-1369, Elsevier B.V., Netherlands (Oct. 2013). [cited by applicant]
Dolton, G., et al., “More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers,” Immunology 146(1):11-22, Wiley-Blackwell Publishing LTD., United Kingdom (Sep. 2015). [cited by applicant]
Feldman, S., et al., “Adoptive Cell Therapy—Tumor-infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors,” Semin Oncol 42(4):626-639, W.B. Saunders, United States (Aug. 2015). [cited by applicant]
Hirano, N., et al., “Autoantibodies frequently detected in patients with aplastic anemia,” Blood 102(13):4567-4575, Elsevier B.V., United States (Dec. 2003). [cited by applicant]
Hirano, N., et al., “Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses,” Clin Cancer Res 12(10):2967-2975, Amer… [cited by applicant]
Hirano, N., et al., “Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity,” Blood, 107(4): 1528-1536, Elsevier B.V., United States (Feb. 2006). [cited by applicant]
Hirano, N., et al., “Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia,” Blood 108(8):2662-2668, Elsevier B.V., Unit… [cited by applicant]
Imataki, O., et al., “IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells,” J Immunol 188(4):1609-1619, American Association of Immunologists, United Stat… [cited by applicant]
International Search Report and Written Opinion issued in International Patent Application No. PCT/CA2017/000102, dated Jul. 13, 2017, 9 pages. [cited by applicant]
Kagoya, Y., et al., “BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models” J. Clin. Invest 126(9):3479-3494, The American Society for Clinical Investigation, United States… [cited by applicant]
Kawana-Tachikawa, A., et al., “An efficient and versatile mammalian viral vector system for major histocompatibility complex class I/ peptide complexes,” Journal of Virology 76(23):11982-11988, American Society for Micr… [cited by applicant]
Kawase, T., et al., “Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen,” Blood 110(3):1055-1063, Elsevier B.V., United States (Aug. 2007). [cited by applicant]
Klenerman, P., et al., “Tracking T cells with tetramers: new tales from new tools,” Nat Rev Immunol 2(4):263-272, Nature Publishing Group, United Kingdom (Apr. 2002). [cited by applicant]
Laugel, B., et al., “Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties,” J Biol Chem 282(33):23799-23810, American Socie… [cited by applicant]
Marrack, P., et al., “Evolutionarily conserved amino acids that control TCR-MHC interaction” Annu Rev Immunol 26:171-203, Annual Reviews Inc., United States (2008). [cited by applicant]
Migueles, S., et al., “HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors,” Proc Natl Acad Sci U.S.A. 97(6):2709-2714, National Academy of Scienc… [cited by applicant]
Nakatsugawa, M., et al., “Specific roles of each TCR hemichain in generating functional chain-centric TCR,” J Immunol 194(7):3487-3500, American Association of Immunologists, United States (Apr. 2015). [cited by applicant]
Nguyen, L., et al., “Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs),” PLoS One 5(11):e13940, Public Library of Science, United States (Nov. 2010). [cited by applicant]
NIH Tetramer Core Facility, “Production Protocols—Class I MHC Tetramer Preparation: Overview,” accessed at URL:[https://tetramer.yerkes.emory.edu/support/protocols] on May 21, 2021, 21 pages. [cited by applicant]
Ochi, T., et al., “Optimization of T-cell reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy,” Cancer Immunol Res 3(9):1070-1081, American Association for Canc… [cited by applicant]
Parker, K., et al., “Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains,” J Immunol 152(1):163-175, American Association of Immunologists, United States (… [cited by applicant]
Robbins, P., et al., “Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells,” Nat Med 19(6):747-752, Nature Publishing Group, United Kingdom (Jun. 2013). [cited by applicant]
Rodenko, B., et al., “Generation of peptide-MHC class I complexes through UV-mediated ligand exchange,” Nature Protocols 1(3):1120-1132, Nature Publishing Group, United Kingdom (Aug. 2006). [cited by applicant]
Rossjohn, J., et al., “T cell antigen receptor recognition of antigen-presenting molecules,” Annu Rev Immunol 33:169-200, Annual Reviews Inc., United States (Dec. 2014). [cited by applicant]
Saini, S., et al., “Dipeptides catalyze rapid peptide exchange on MHC class molecules,” Proc Natl Acad Sci 112(1):202-207, National Academy of Sciences, United States (Jan. 2015). [cited by applicant]
Stevens, J., et al., “Efficient Generation of Major Histocompatibility Complex Class I—Peptide Complexes Using Synthetic Peptide Libraries,” Journal of Biological Chemistry 273(5):2874-2884, Elsevier Inc. on behalf of A… [cited by applicant]
Tanaka, M., et al., “Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell,” Clin Cancer Res 17(16):5392-5401, American Association for Cancer Research Inc., Uni… [cited by applicant]
Truscott, S., et al., “Human Major Histocompatibility Complex (MHC) Class I Molecules with Disulfide Traps Secure Disease-related Antigenic Peptides and Exclude Competitor Peptides,” Journal of Biological Chemistry 283(… [cited by applicant]
UniProt, “UniProtKB—Q16655 (MAR1_Human)” Nov. 1, 1997, URL <https://www.uniprot.org/uniprot/Q16655 >. [cited by applicant]
Vitiello, A., et al., “Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex,” Journal of Experimen… [cited by applicant]
Wooldridge, L., et al., “Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region,” Eur J Immunol 37(5): 1323-1333, Wiley-VCH Verlag, Germany (May 2007). [cited by applicant]
Wooldridge, L., et al., “MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs,” J Immunol 184(7):3357-3366, American Associ… [cited by applicant]
Wooldridge, L., et al., “Tricks with tetramers: how to get the most from multimeric peptide-MHC,” Immunology 126(2):147-164, Wiley-Blackwell Publishing Ltd., United Kingdom (Feb. 2009). [cited by applicant]
Non-Final Office Action mailed Aug. 30, 2021, in U.S. Appl. No. 16/095,913, Hirano, N., et al., filed Oct. 23, 2018, 9 pages. [cited by applicant]
NCBI, “Chain A, MHC Class I Histocompatibility Antigen (HLA-A*0201) (Alpha Chain),” PDB: 1AKJ_A, accessed at https://www.ncbi.nlm.nih.gov/protein/1AKJ_A/, 2 pages (May 1997). [cited by applicant]